What We're Reading: Page 317
Industry reads hand-picked by our editors
Nov 16, 2016
-
Nature
CRISPR gene-editing tested in a person for the first time
-
The Wall Street Journal
Walgreens claims Theranos voided 11.3% of test reports
-
Bloomberg Gadfly
Teva's scale needs to start paying off soon
-
Financial Times
US casts shadow on Novo Nordisk ahead of 'perfect storm'
Nov 15, 2016
Nov 14, 2016
-
Bloomberg
Novartis said to hold talks to buy generics maker Anneal
-
Financial Times
US election boosts BlackRock biotech exchange traded fund
-
Forbes
Are Naproxen and Ibuprofen sometimes risky? A controversial study of Celebrex raises concerns
-
GEN News
Sanofi Genzyme opts in to one Alnylam candidate, passes on another
Nov 11, 2016
-
Reuters
Valeant may seek to clean up its name by changing it - Ackman
-
The Economist
How to enroll your dog in a cancer-drug trial
-
Bloomberg
Saving heroin users with a nasal spray is an $80 million business
-
SupplyChain Dive
How CVS, Walgreens battle for market share through their supply chains
-
CB Insights
The rise of cancer startup exits in one infographic
Nov 10, 2016
Nov 09, 2016
-
The Wall Street Journal
Pharma stocks benefit from U.S. election result, but relief may be fleeting
-
The Washington Post
Drug companies just scored a big election victory
-
Business Insider
Trump's victory could give Europe's pharmaceutical industry a big boost
-
Bloomberg
Another Canada drugmaker trips after debt-fueled deal spree
Nov 08, 2016
-
Business Insider
Leaked documents shed light on the defunct pharmacy that brought Valeant to its knees
-
The Washington Post
The bizarre reason two competing drug prices rose in tandem
-
Reuters
Stanford uses CRISPR to correct sickle cell, human trials planned
-
Bloomberg
Drug prices to drop regardless of U.S. vote outcome, Witty says
Previous
